# A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden

> **NCT03328364** · — · COMPLETED · sponsor: **Astellas Pharma a/s** · enrollment: 211 (actual)

## Conditions studied

- Metastatic Castration Resistant Prostate Cancer

## Interventions

- **DRUG:** enzalutamide
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT03328364
- **Lead sponsor:** Astellas Pharma a/s
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2017-12-24
- **Final completion:** 2017-12-24
- **Target enrollment:** 211 (ACTUAL)
- **Last updated:** 2024-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328364, "A Registry Based Study Evaluating Overall Survival and Treatment Length in mCRPC Patients Treated With Enzalutamide in Sweden". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03328364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*